The following is what Smith mentions in his comments section below his article on Cubist buying out Trius:
"The price does seem low to me and I think that there is some chance of someone else coming in. Any big pharma with a hospital sales force could fold tedizolid into their portfolio with no issue. This includes Merck, Pfizer, Eli Lilly, Glaxo and Aztra Zeneca. Perhaps we will see another party coming in or perhaps Cubist will sweeten the offer. I think I will hold on to my shares."
I read his article from a while back and that's what got me into TSRX. I'm grateful for that, and he seems like a very trustworthy writer. Definitely worth considering his opinion. Anyway, I sold my shares after-hours because I'm still not a very experienced investor. Made a nice a profit, but I hope you all do much better.